ID Week 2023

References for Poster 639

1. Ahava MJ, Kurkela S, Kuivanen S, Lappalainen M, Jarva H, Jaaskelainen AJ. Detection of SARS-CoV-2 nucleocapsid antigen from serum can aid in timing of COVID-19 infection. J Virol Methods. Apr 2022;302:114469. doi:10.1016/j.jviromet.2022.114469

2. Chenane HR, Menidjel R, Lebourgeois S, et al. SARS-CoV-2 N-antigen sera levels are associated with COVID-19 prognostic value [CROI Abstract 197]. Top Antiv Med. 2022;30(1s)

3. Damhorst GL, Schoof N, Nguyen PV, et al. Investigation of Blood Plasma Viral Nucleocapsid Antigen as a Marker of Active Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant Infection. Open Forum Infect Dis. May 2023;10(5):ofad226. doi:10.1093/ofid/ofad226

4. Damhorst GL, Verkerke HP, Harrington KRV, et al. SARS-CoV-2 Antigenemia is Associated With Pneumonia in Children But Lacks Sensitivity to Diagnose Acute Infection. Pediatr Infect Dis J. Feb 1 2023;42(2):130-135. doi:10.1097/INF.0000000000003779

5. Favresse J, Bayart JL, David C, Dogne JM, Douxfils J. Nucleocapsid serum antigen determination in SARS-CoV-2 infected patients using the single molecule array technology and prediction of disease severity. J Infect. Apr 2022;84(4):e4-e6. doi:10.1016/j.jinf.2022.01.023

6. Favresse J, Bayart JL, David C, et al. Serum SARS-CoV-2 Antigens for the Determination of COVID-19 Severity. Viruses. Jul 28 2022;14(8)doi:10.3390/v14081653

7. Group A-TS, Rogers AJ, Wentworth D, et al. The Association of Baseline Plasma SARS-CoV-2 Nucleocapsid Antigen Level and Outcomes in Patients Hospitalized With COVID-19. Ann Intern Med. Oct 2022;175(10):1401-1410. doi:10.7326/M22-0924

8. Hingrat QL, Visseaux B, Laouenan C, et al. Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives. Clin Microbiol Infect. Dec 8 2020;27(5):789 e1-5. doi:10.1016/j.cmi.2020.11.025

9. Verkerke H, Harrington K, McLendon K, et al. Longitudinal assessment of SARS-CoV-2 nucleocapsid antigenemia in patients hospitalized with COVID-19. American Journal of Clinical Pathology. Oct 2021;156(Supplement_1):S1-S1. doi:10.1093/ajcp/aqab189.000

10. Verkerke HP, Damhorst GL, Graciaa DS, et al. Nucleocapsid Antigenemia Is a Marker of Acute SARS-CoV-2 Infection. J Infect Dis. Nov 1 2022;226(9):1577-1587. doi:10.1093/infdis/jiac225

11. Veyrenche N, Pisoni A, Debiesse S, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Antigen in Urine of Hospitalized Patients With Coronavirus Disease 2019. J Infect Dis. Sep 13 2022;226(5):812-821. doi:10.1093/infdis/jiac073

12. Wang H, Hogan CA, Verghese M, et al. SARS-CoV-2 Nucleocapsid Plasma Antigen for Diagnosis and Monitoring of COVID-19. Clin Chem. Dec 30 2021;68(1):204-213. doi:10.1093/clinchem/hvab216

13. Wick KD, Leligdowicz A, Willmore A, et al. Plasma SARS-CoV-2 nucleocapsid antigen levels are associated with progression to severe disease in hospitalized COVID-19. Crit Care. Sep 14 2022;26(1):278. doi:10.1186/s13054-022-04153-3

14. Zhang Y, Ong CM, Yun C, et al. Diagnostic Value of Nucleocapsid Protein in Blood for SARS-CoV-2 Infection. Clin Chem. Dec 30 2021;68(1):240-248. doi:10.1093/clinchem/hvab148

15. Ogata AF, Maley AM, Wu C, et al. Ultra-Sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease. Clin Chem. Dec 1 2020;66(12):1562-1572. doi:10.1093/clinchem/hvaa213

16. Sigal GB, Novak T, Mathew A, et al. Measurement of Severe Acute Respiratory Syndrome Coronavirus 2 Antigens in Plasma of Pediatric Patients With Acute Coronavirus Disease 2019 or Multisystem Inflammatory Syndrome in Children Using an Ultrasensitive and Quantitative Immunoassay. Clin Infect Dis. Oct 12 2022;75(8):1351-1358. doi:10.1093/cid/ciac160

17. Mathur S, Davidson MC, Anglin K, et al. Evaluation of Severe Acute Respiratory Syndrome Coronavirus 2 Nucleocapsid Antigen in the Blood as a Diagnostic Test for Infection and Infectious Viral Shedding. Open Forum Infect Dis. Nov 2022;9(11):ofac563. doi:10.1093/ofid/ofac563

18. Oueslati S, Manai Bouokazi M, Ramdhani I, et al. Clinical Added Value of SARS-CoV-2 Antigen Detection in Blood Samples. Diagnostics (Basel). Oct 7 2022;12(10)doi:10.3390/diagnostics12102427

19. Blain H, Tuaillon E, Gamon L, et al. Receptor binding domain-IgG levels correlate with protection in residents facing SARS-CoV-2 B.1.1.7 outbreaks. Allergy. Jun 2022;77(6):1885-1894. doi:10.1111/all.15142

20. Zhang W, Liu W, Lin J, et al. Highly Prevalent SARS-CoV-2 Antigenemia in COVID-19 Patients. Infect Dis Immun. Jul 2022;2(3):193-199. doi:10.1097/ID9.0000000000000057

21. Thudium RF, Stoico MP, Hogdall E, et al. Early Laboratory Diagnosis of COVID-19 by Antigen Detection in Blood Samples of the SARS-CoV-2 Nucleocapsid Protein. J Clin Microbiol. Sep 20 2021;59(10):e0100121. doi:10.1128/JCM.01001-21

22. Martin-Vicente M, Almansa R, Martínez I, et al. Low anti-SARS-CoV-2 S antibody levels predict increased mortality and dissemination of viral components in the blood of critical COVID-19 patients. Journal of internal medicine. Feb 2022;291(2):232-240. doi:10.1111/joim.13386

23. Brasen CL, Christensen H, Olsen DA, et al. Daily monitoring of viral load measured as SARS-CoV-2 antigen and RNA in blood, IL-6, CRP and complement C3d predicts outcome in patients hospitalized with COVID-19. Clin Chem Lab Med. Nov 25 2021;59(12):1988-1997. doi:10.1515/cclm-2021-0694

24. Shan D, Johnson JM, Fernandes SC, et al. N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection. Nat Commun. Mar 26 2021;12(1):1931. doi:10.1038/s41467-021-22072-9